A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Acquisition of Pre-Merger Spyre On June 22, 2023, we acquired Pre-Merger Spyre pursuant to that certain Agreement and Plan of Merger (the “Acquisition Agreement”), dated June 22, 2023, by and among us, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Sequoia Merger Sub II, LLC, a Delaware limited liability company and one of our wholly owned subsidiaries, and Pre-Merger Spyre. Pre-Merger Spyre was a pre-clinical stage biotechnology company that was incorporated on April 28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. Through the Asset Acquisition, we received the option to license certain intellectual property rights related to four research programs (collectively, the "Option").
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 886K | - | - |
| Net Income | -155M | -155M | -208M | - | -84M | -66M |
| EPS | $-79.02 | $-79.02 | $-127.21 | $-550.29 | $-621.50 | $-625.50 |
| Free Cash Flow | -169M | -169M | -157M | -100M | -80M | -54M |
| ROIC | -26.3% | -25.2% | -40.2% | - | -166.6% | -58.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.18 | 0.00 | 0.09 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -210M | -210M | -209M | -242M | -85M | -66M |
| Operating Margin | 0.0% | - | - | -27348.0% | - | - |
| ROE | -21.7% | -25.2% | -40.2% | - | -166.6% | -58.8% |
| Shares Outstanding | 79M | 79M | 79M | 60M | 1M | 2M |
Spyre Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Spyre Therapeutics, Inc. (SYRE) has a 5-year average return on invested capital (ROIC) of -72.7%. This is below average and may indicate limited pricing power.
Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $5.0B. It is classified as a mid-cap stock.
Spyre Therapeutics, Inc. (SYRE) does not currently pay a regular dividend.
Spyre Therapeutics, Inc. (SYRE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Spyre Therapeutics, Inc. (SYRE) generated $-169 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Spyre Therapeutics, Inc. (SYRE) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
Spyre Therapeutics, Inc. (SYRE) reported earnings per share (EPS) of $-79.02 in its most recent fiscal year.
Spyre Therapeutics, Inc. (SYRE) has a return on equity (ROE) of -25.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Spyre Therapeutics, Inc. (SYRE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Spyre Therapeutics, Inc. (SYRE) has a book value per share of $9.11, based on its most recent annual SEC filing.